BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
BLRX Stock Chart & Stats
1.50
>-0.01(-6.00%)
At close: 4:00 PM EST
1.50
>-0.01(-6.00%)
Day’s Range― - ―
52-Week Range1.20 - 3.90
Previous CloseN/A
Volume20.50M
Average Volume (3M)4.64M
Market Cap
₪33.94M
Enterprise Value17.87M
Total Cash (Recent Filing)₪20.88M
Total Debt (Recent Filing)₪10.15M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 27, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,610,814,500
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.50M
Bulls Say, Bears Say
Bulls Say
Strategic Joint VentureThe Hemispherian JV spreads late‑stage development cost and scientific risk while leveraging partner expertise. BioLineRx holds an economic stake (initial 40% with potential to increase), preserving upside while reducing capital intensity and accelerating GLIX1 development timelines.
Patent Protection For GLIX1A granted allowance and additional claims for GLIX1 secure multi‑year exclusivity and combination-use coverage across jurisdictions. Durable IP improves bargaining power with partners, supports future royalty streams and helps protect long‑term revenue potential if clinical success is achieved.
Near‑term Cash RunwayA cash balance funding operations into H1 2027 materially reduces near‑term financing urgency, permitting progression of GLIX1 Phase1/2a and ongoing motixafortide studies to key data inflection points and creating optionality to secure milestone or partner funding before runway exhaustion.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates the business cannot self‑fund development. Over months this forces reliance on external capital, partnerships or milestone financings, increasing dilution and risk that programs slow if non‑dilutive funding does not materialize.
Revenue Contraction And VolatilityA sharp TTM revenue decline and volatile top‑line reduce visibility for sustaining overhead and development. Even with a positive gross margin at scale, revenue instability impairs internal reinvestment capacity and weakens negotiating leverage with partners and payors over the medium term.
Reduced Internal R&D And Commercial FootprintLower R&D and elimination of sales/marketing reflect out‑licensing and a leaner operating model but shrink internal capability to advance and commercialize multiple assets independently. Long‑term this increases reliance on partners and raises risk that company value capture depends on third‑party priorities.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.20 and its highest was 3.90 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪33.94M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is May 27, 2026 which is in 49 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Mar 23, 2026. The company reported 0 earnings per share for the quarter, beating the consensus estimate of -0.314 by 0.314.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.63.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,610,814,500 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report, beating expectations of -0.314. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.